{"id":58612,"date":"2015-07-30T20:26:10","date_gmt":"2015-07-31T00:26:10","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=58612"},"modified":"2015-07-30T20:45:16","modified_gmt":"2015-07-31T00:45:16","slug":"on-the-road-again-2","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2015\/07\/30\/on-the-road-again-2\/","title":{"rendered":"on the road again&#8230;"},"content":{"rendered":"<div align=\"justify\" class=\"small\">I&#8217;ve been preoccupied with another project for a month or so, and looking  at my posts, it shows. I&#8217;m afraid they&#8217;re kind of just <font color=\"#200020\">newsy<\/font> as a result. But I&#8217;m  free of those distractions at last, and looked forward to catching up on the current state of play. So I headed for one of my usual resources, arriving just in time to say goodbye &#8211; again&#8230;       <\/div>\n<blockquote>\n<div align=\"center\" class=\"big\">           <a target=\"_blank\" href=\"http:\/\/blogs.wsj.com\/pharmalot\/2015\/07\/30\/pharmalot-pharmawhat-until-we-meet-again\/\">Pharmalot&hellip; PharmaWhat?&hellip; Until We Meet Again&hellip;<\/a> <\/div>\n<div align=\"center\" class=\"big\"><strong><font color=\"#004400\">Pharmalot <\/font><\/strong><\/div>\n<div align=\"center\" class=\"middle\">By Ed Silverman<\/div>\n<div align=\"center\" class=\"small\">June 30, 2015 <\/div>\n<p align=\"justify\">Once again, another working week will soon draw to a close and &ndash;  along with it &ndash; the latest iteration of Pharmalot. Yes, you got that  right. After a brief, but rewarding stay here at The Wall Street  Journal, we are taking our act to a different theater. As our bubbe used  to say &ndash; the only constant is change.<\/p>\n<p align=\"justify\">Before discussing our destination, we would like to thank the many  long-standing Pharmalot readers and, of course, the more recent  arrivals, who make Pharmalot an exceptionally interesting and  pleasurable experience. Without your feedback &ndash; whether posted online or  sent privately &ndash; this gig would not be nearly as fulfilling. You know  who you are.<\/p>\n<p align=\"justify\">Over the years, in fact, we have come to regard the Pharmalot  community as something of a virtual garden party, where news emerges,  views are swapped and insights are gained. And we are better off having  absorbed the suggestions, criticisms and, of course, the juicy tips. We  would be remiss, however, if we did not thank Dennis Berman and Stefanie  Ilgenfritz for their helpful stewardship during our tenure here.<\/p>\n<p align=\"justify\">As for our next step, we are shifting our Pharmalot endeavors to  Stat, a forthcoming website that will devote itself to tracking the  fascinating ins and outs of life sciences. For those who are unaware,  Stat will emerge out from under the umbrella of The Boston Globe.  Further details will become available shortly. Meanwhile, you can reach  us at <a href=\"mailto:pharmalot@gmail.com\">pharmalot@gmail.com<\/a> and follow the usual <a href=\"https:\/\/twitter.com\/pharmalot\">@pharmalot<\/a> Twitter handle.<\/p>\n<div align=\"justify\">And now, the time has come to daydream about weekend plans. Have a wonderful summer and see you online soon.<\/div>\n<\/blockquote>\n<div align=\"justify\" class=\"small\">In January of 2014, <strong><font color=\"#004400\">Pharmalot<\/font><\/strong> went away from being hosted on <strong><font color=\"#200020\"><em>Pharma<\/em>L<\/font><font color=\"#990000\">i<\/font>ve<\/strong> [<a target=\"_blank\" href=\"http:\/\/1boringoldman.com\/index.php\/2014\/01\/01\/gulp-8\/\">gulp&hellip;<\/a>], returning to the <strong><font color=\"#000001\">Wall Street Journal<\/font><\/strong> a year ago [<a target=\"_blank\" href=\"http:\/\/1boringoldman.com\/index.php\/2014\/06\/04\/oh-how-weve-missed-our-pharmalot\/\">oh how we&rsquo;ve missed our <strong><font color=\"#004400\">Pharmalot<\/font><\/strong>!&hellip;<\/a>]. Now it appears Ed Silverman is on the road again. This time, he&#8217;s moving to a new Boston Globe initiative called <font color=\"#200020\">STAT<\/font>:<\/div>\n<blockquote>\n<div align=\"center\" class=\"big\"><a href=\"http:\/\/talkingbiznews.com\/1\/pharmalot-blogger-silverman-joining-boston-globe\/\" target=\"_blank\">Pharmalot blogger Silverman joining Boston Globe<\/a><\/div>\n<div align=\"center\" class=\"big\"><strong><font color=\"#200020\">Talking Biz News <\/font><\/strong><\/div>\n<div align=\"center\" class=\"middle\">by Chris Roush<\/div>\n<div align=\"center\" class=\"small\"> July 30, 2015<\/div>\n<p align=\"justify\"><strong>Ed Silverman<\/strong>, the Wall Street Journal reporter who runs the Pharmalot blog that covers the drug industry, is joining the Boston Globe. With the Globe, Silverman will be joining the Globe&rsquo;s new health care  news called Stat that debuts in the fall. He&rsquo;ll be taking Pharmalot  with him and writing a weekly column, too.<\/p>\n<div align=\"justify\">Silverman had been laid off from the Journal last month&#8230;<\/div>\n<\/blockquote>\n<blockquote>\n<div align=\"center\" class=\"big\"><a target=\"_blank\" href=\"http:\/\/www.poynter.org\/news\/mediawire\/358781\/boston-globes-life-sciences-initiative-finally-has-a-name-stat\/\">Boston Globe&rsquo;s life sciences initiative finally has a name &ndash; &lsquo;Stat&rsquo;<\/a><\/div>\n<div align=\"center\" class=\"middle\"><strong><font color=\"#200020\">Poynter.org<\/font><\/strong> <\/div>\n<div align=\"center\" class=\"middle\">by Gurman Bhatia<\/div>\n<div align=\"center\" class=\"small\">July 17, 2015<\/div>\n<p align=\"justify\">The <a target=\"_blank\" href=\"http:\/\/www.poynter.org\/news\/mediawire\/342345\/inside-the-upcoming-life-sciences-newsroom-from-boston-globe-media\/\">Boston Globe&rsquo;s life sciences initiative<\/a>  led by former Politico executive editor Rick Berke now finally has a  name. They want you to read the news urgently, hence &ndash; Stat. The name, which evokes urgency, is a reference to the medical term  stat. Stat is derived from a Latin word that means &ldquo;immediately.&rdquo; The company acquired the domain <a href=\"http:\/\/statnews.com\/\" target=\"_blank\">www.statnews.com<\/a> on Thursday. Berke  later made it official with an announcement in a staff meeting Friday. &ldquo;We take you inside science labs and hospital wards, biotech  boardrooms and political backrooms,&rdquo; Stat&rsquo;s mission statement reads.  &ldquo;Stat&nbsp;will examine controversies, introduce power brokers and puncture  hype.&rdquo;<\/p>\n<p align=\"justify\">Stat&rsquo;s leadership ranks include Gideon Gil, managing editor of  enterprise and partnerships and Jeff DelViscio, who is senior editor of  multimedia and creative. Gil was the former health and science editor of  The Globe and DelViscio was a Web producer on the science and  environment desk of The New York Times. While Stat is still hush-hush about who it has hired, Berke said the  reporters&rsquo; names will be recognizable once they&rsquo;re disclosed.<\/p>\n<p align=\"justify\">The company is also looking to hire for at least <a target=\"_blank\" href=\"https:\/\/chc.tbe.taleo.net\/chc05\/ats\/careers\/searchResults.jsp;?org=BOSTGLOB&#038;cws=1\">six senior positions for the Stat multimedia team<\/a>.  DelViscio&rsquo;s ambition is to incorporate video, photo and interactive  content within Stat&rsquo;s storytelling stream. These jobs include a video  editor, an interactives editor and a social media editor. DelViscio aims  at integrating a full-stack multimedia team in the newsroom, drawing on  its expertise from the very beginning of the storytelling process. &ldquo;It is also a question of what constitutes a multimedia element,&rdquo;  DelViscio said. &ldquo;Often something as simple as a GIF can have a little  impact on the story, in sort of a teaching mentality. There is a visual  quality to the life sciences that is often not utilized.&rdquo; <\/p>\n<p align=\"justify\">The initiative can be expected to feature both short and longform  video, be it shareable short clips focused towards social media, or  mini-documentary style footage. With the interactives editor, the aim is  to explore data visualization and the potential on that side right from  the start. &ldquo;At its core, Stat is supposed to be a watchdog,&rdquo; DelViscio said.  &ldquo;There is so much money in the system and no people are looking at it  consistently. That is the huge part of our mission. Although we are at a  nascent stage right now, the possibilities also include searchable  databases for public health information that aren&rsquo;t otherwise readily  accessible, something places like ProPublica and Center for Public  Integrity do so well.&rdquo;<\/p>\n<div align=\"justify\">Although the website doesn&rsquo;t have a launch date yet, the team would  start publishing Stat-branded content on The Boston Globe in late  summer. Staffers would work towards building a national audience with  that and promotion on social media. According to Berke, Stat has recruited people in Boston, New York,  Washington, D.C. and the West Coast. &ldquo;This will eventually be of  national scope,&rdquo; he said. What used to be a formal-looking publisher suite on the third floor  of the Boston Globe building is now being revamped for Stat. The launch  date is still several months away, but as the team works on creating an  office space and reporters come in, Berke says it already has the feel  of an excellent newsroom.<\/div>\n<\/blockquote>\n<div align=\"justify\" class=\"small\">It actually sounds like a good move for his blog. What&#8217;s important is that Ed doesn&#8217;t go away. He&#8217;s been at it for fifteen years, and obviously has a network of information sources that almost guarantees that if something happens, he&#8217;ll be telling us about it pronto. So, in his absence, here&#8217;s a predictable offering [GSK&#8217;s bribery program is apparently up to speed]:<\/div>\n<blockquote>\n<div align=\"center\" class=\"big\"><a target=\"_blank\" href=\"http:\/\/www.reuters.com\/article\/2015\/07\/29\/us-gsk-romania-corruption-exclusive-idUSKCN0Q32A920150729\">Exclusive: GSK faces new corruption allegations, this time in <font color=\"#990000\">Romania<\/font><\/a><\/div>\n<div align=\"center\" class=\"big\">             <strong><font color=\"#200020\">Reuters<\/font><\/strong><\/div>\n<div align=\"center\" class=\"middle\">By Ben Hirschler<\/div>\n<div align=\"center\" class=\"small\">Jul 29, 2015<\/div>\n<p>Drugmaker <a href=\"http:\/\/www.reuters.com\/finance\/stocks\/overview?symbol=GSK\">GlaxoSmithKline<\/a>, which was fined a record 3 billion yuan ($483 million) for corruption in China last year and is examining possible staff misconduct elsewhere, faces new allegations of bribery in Romania.<\/p>\n<p>GSK  confirmed it was looking into the latest claims of improper payments  set out in a whistleblower&#8217;s email sent to its top management on Monday.  A copy of the email was seen by Reuters.<\/p>\n<div>The company is already probing alleged bribery in <strong><font color=\"#990000\">Poland<\/font><\/strong>,<strong><font color=\"#990000\"> the United Arab Emirates<\/font><\/strong>,<strong><font color=\"#990000\"> Lebanon<\/font><\/strong>,<strong><font color=\"#990000\"> Jordan<\/font><\/strong>, <strong><font color=\"#990000\">Syria <\/font><\/strong>and<strong><font color=\"#990000\"> Iraq<\/font><\/strong>&#8230;<\/div>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>I&#8217;ve been preoccupied with another project for a month or so, and looking at my posts, it shows. I&#8217;m afraid they&#8217;re kind of just newsy as a result. But I&#8217;m free of those distractions at last, and looked forward to catching up on the current state of play. So I headed for one of my [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-58612","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/58612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=58612"}],"version-history":[{"count":10,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/58612\/revisions"}],"predecessor-version":[{"id":58622,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/58612\/revisions\/58622"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=58612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=58612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=58612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}